This study is currently not recruiting participants.

CBGJ398XUS04; Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations

Study on Investigational Treatment for FGFR Pathway-Regulated Tumors

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The purpose of this signal seeking study is to determine whether treatment with BGJ398 demonstrates sufficient efficacy in select FGFR pathway-regulated solid tumors and/or hematologic malignancies to warrant further study.

Detailed description of study

The purpose of this signal seeking study is to determine whether treatment with BGJ398 demonstrates sufficient efficacy in select FGFR pathway-regulated solid tumors and/or hematologic malignancies to warrant further study.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: hematologic malignancies
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the effectiveness of an investigational medication in treating solid tumors and blood cancers that are regulated by the FGFR pathway. The FGFR pathway is a series of proteins in the body that helps cells grow and divide. When this pathway is altered, it can lead to cancer.

Participants will receive the investigational medication to see how it affects their cancer. The study will monitor the participants' response to the treatment to determine if it is effective enough for further research.

  • Who can participate: Individuals aged 18 and older with diagnosed solid tumors or blood cancers regulated by the FGFR pathway may be eligible to participate. Additional eligibility criteria include specific health conditions and prior treatment history.
  • Study details: Participants will receive the investigational medication and their response to the treatment will be closely monitored. This will help researchers understand if the medication is effective in treating cancers related to the FGFR pathway.
Updated on 19 Feb 2024. Study ID: 1409996156

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team